Autologous stem-cell transplantation can be performed safely without the use of blood-product support

Journal of Clinical Oncology

Volumn 22, Issue 20, 2004, Pages 4087-4094

  Ballen, Karen K ^a   Becker, Pamela S ^a   Yeap, Beow Yong ^a   Matthews, Barbara ^a   Henry, David H ^a   Ford, Patricia A ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 11; IRON;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; HUMAN; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; RELIGION; SAFETY; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; ADULT; AUTOTRANSPLANTATION; CLINICAL TRIAL; FEMALE; JEHOVAH'S WITNESS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; COMBINED MODALITY THERAPY; ERYTHROPOIETIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMORRHAGE; HUMANS; INTERLEUKIN-11; JEHOVAH'S WITNESSES; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET COUNT; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS;

EID: 7044260728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.144     Document Type: Article

References (52)

1. Prince HM, Imrie K, Crump M, et al: The role of intensive chemotherapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of prognostic groups. Br J Haematol 92:880-889, 1996
2. Yuen A, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822, 1997
3. Armitage JO: Bone marrow transplantation. N Engl J Med 330:827-838, 1994
4. Altal M, Harousseau JL, Stoppa AM. et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 335:91-97, 1996
5. Nevo S, Swan V, Enger C, et al: Acute bleeding after bone marrow transplantation (BMT): Incidence and effect on survival-A quantitative analysis in 1,402 patients. Blood 91:1469-1477, 1998
6. McKay PJ, Murphy JA, Camerson S, et al: Iron overload and liver dysfunction after allogenenic and autologous bone marrow transplantation. Bone Marrow Transplant 17:63-66, 1996
7. Bernstein SH, Nademanee AP, Vose JM, et al: A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic stem cell transplantation. Blood 91:3509-3517, 1998
8. Dixon JL, Smalley MG: The surgical/ethical challenge. JAMA 246:2471-2472, 1981
9. The Holy Bible. Leviticus, Chapter 17, Verse 27
10. The Watchtower. October, 2000
11. Ford PA, Borghaei J, Henry DH: Treatment of patients who refuse blood components, in Alving BM (ed): Blood Component and Pharmacologic agents in the treatment of congenital and acquired bleeding disorders. Bethesda, MD, AABB Press, 2000
12. Viele MK, Weiskopf RB: What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 34:396-401, 1993
13. Rosengart TK, Helm RE: DeBois WJ, et al: Open heart operations without transfusion using a multimodality blood conservation strategy in Jehovah's Witnesses patients: Implications for a "bloodless" surgical technique. J Am Coll Surg 184:618-629, 1997
14. Spence RK: The status of bloodless surgery. Transfus Med Rev 5:274-286, 1991
15. Tepler I, Elias L, Smith JW, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607-3614, 1996
16. Auerbach M, Ballard H, Trout JR, et al: Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307, 2004
17. Bartholomew JR, Salgia R, Bell WR: Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch Intern Med 149:1959-1961, 1989
18. Sakariassen KS, Cattaneo M, van der Berg A, et al: DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 64:229-236, 1984
19. Clark JH, Nelson W. Lyons C, et al: Chronic shock: The problem of reduced blood volume in the chronically ill patient. Ann Surg 125:618-623, 1947
20. Czer LSC, Shoemaker WC: Optimal hematocrit value in critically ill postoperative patients. Surg Gynecol Obstet 147:363-368, 1978
21. Jackson BR, Busch MP, Stramer SL, et al: The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43:721-729, 2003
22. US Food and Drug Administration: Guidance for industry: Recommendations for the assessment of donor suitability and blood and product safety in cases of known or suspected West Nile virus infection, October 2002
23. Eschbach J, Abdukhadi M, Browne J, et al: Recombinant human erythropoietin in anemic patients with end stage renal disease. Ann Intern Med 111:992-1000, 1989
24. Schapira L, Antin JH, Ransil BJ, et al: Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76:2354-2359, 1990
25. Miller CB, Jones RJ, Zahurak ML, et al: Impaired erythropoietin response to anemia after bone marrow transplantation. Blood 80:2677-2682, 1992
26. Henry DH, Spivak JL: Clincal use of erythropoietin. Curr Opin Hematol 2:118-124, 1995
27. Klaesson S, Ringden O, Ljungman P, et al: Reduced blood transfusion requirements after allogeneic bone marrow transplantation: Results of a randomized, double blind study with high dose erythropoietin. Bone Marrow Transplant 13:397-402, 1994
28. Ayash LJ, Elias A, Hunt M, et al: Recombinant human erythropoietin for the treatment of the anemia associated with autologous bone marrow transplantation. Br J Haematol 87:153-161, 1994
29. Miller CB, Mills S: Erythropoietin after bone marrow transplantation. Hematol Oncol Clin North AM 8:975-992, 1994
30. Locatelli F, Zecca M, Pedrazzoli P, et al: Use of recombinant erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: Effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 13:403-410, 1994
31. Goodnough LT, Skikne B, Brugnara C, et al: Erythropoietin, iron, and erythropoiesis. Blood 96:823-833, 2000
32. Smoller BR, Kruskall MS: Phlebotomy for diagnostic laboratory tests in adults. N Engl J Med 314:1233-1235, 1986
33. Schuster MW, Beveridge R, Frei-Lahr D, et al: The effects of pegylated recombinant human megakaryocyte growth and development factor on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 30:1044-1050, 2002
34. Ghalib R, Levine C, Hassan M, et al: Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 37:1165-1171, 2003
35. Vredenburgh JJ, Hussein A, Fisher D, et al: A randomized trial of recombinant human interleukin 11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. Biol Blood Marrow Trans 4:134-141, 1998
36. Mannucci PM: Hemostatic Drugs. N Engl J Med 339:245-253, 1998
37. Delrossi AJ, Cernaianu AC, Botros S, et al: Prophylactic treatment of postperfusion bleeding using EACA. Chest 96:27-30, 1989
38. Daily PO, Lamphere JA, Dembitsky WP, et al: Effect of prophylactic epsilon aminocaproic acid on blood loss and transfusion requirement in patients undergoing first time coronary artery bypass grafting: A randomized, prospective, double blind study. J Thorac Cardiovasc Surg 108:99-106, 1994
39. Vander Salm TJ, Kaur S, Lancey RA, et al: Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 112:1098-1107, 1996
40. Estrin JT, Ford PA, Henry DH, et al: Erythropoietin permits high-dose chemotherapy with peripheral blood stem-cell transplant for Jehovah's Witness. Am J Hematol 33:51-52, 1997
41. Attal M, Harousseau JL, Facon T, et al: Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 349:2495-2502, 2003
42. Corrandini P, Ladetto M, Zallio F, et al: Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be obtained only in follicular subtypes. J Clin Oncol 22:1460-1468, 2004
43. Ballen KK, Ford PA, Waitkus H. et al: Successful autologous bone marrow transplant without the use of blood product support. Bone Marrow Transplant 26:227-229, 2000
44. Knuti KA, Amrein PA, Chabner BA, et al: Faith, identity, and leukemia: When blood products are not an option. Oncologist 7:371-380, 2002
45. Kerridge I, Lowe M, Seldon M, et al: Clinical and ethical issues in the treatment of Jehovah's Witnesses with acute myeloblastic leukemia. Arch Intern Med 157:1753-1757, 1998
46. Marsh JC, Bevan DH: Haematological care of the Jehovah's Witness patient. Br J Haematol 119:25-37, 2002
47. Mazza P, Prudenzano A, Amurri B, et al: Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: Single center experience. Bone Marrow Transplant 32:433-436, 2003
48. Dey BR, McAfee S, Sackstein R, et al: Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation. Biol Blood Marrow Transplant 7:604-612, 2001
49. Weissinger F, Sandmaier BM. Maloney DG, et al: Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 98:3584-3588, 2001
50. Ballen KK, Becker PS, Emmons RVB, et al: Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood 100:442-450, 2002
51. Zenz T, Dohner H, Bunjes D: Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's Witness. Bone Marrow Transplant 32:437-438, 2003
52. Baron F, Frere P, Fillet G, et al: Tandem high-dose therapy (HDT) for multiple myeloma: Recombinant human erythropoietin therapy given between first and second HDT allows second peripheral stem cell transplant without red blood cell transfusion. Br J Haematol 123:103-105, 2003